Novo Nordisk Q1 earnings: Growth forecast trimmed as GLP-1 compounder ban yet to go live
Novo Nordisk said on Wednesday that compounding pharmacies’ production of its GLP-1 medicine semaglutide had reduced its market penetration more dramatically than it had expected — causing it to cut its full ...
Novo Nordisk said on Wednesday that compounding pharmacies’ production of its GLP-1 medicine semaglutide had reduced its market penetration more dramatically than it had expected — causing it to cut its full ...
